SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, PPE, Licensing and Research (Details) - USD ($)	1 Months Ended		3 Months Ended								12 Months Ended
	Feb. 29, 2016	Oct. 31, 2014	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Research and Product Development
Product development and research costs			$ 1,200,729	$ 1,261,863	$ 2,063,324	$ 1,314,430	$ 2,029,736	$ 1,246,727	$ 885,259	$ 799,591	$ 5,840,346	$ 4,961,313	$ 7,783,594
Minimum
PROPERTY AND EQUIPMENT
Useful life											3 years
Maximum
PROPERTY AND EQUIPMENT
Useful life											10 years
Wanbang Biopharmaceutical
Revenue Recognition
Upfront payment	$ 4,000,000
Baxter Healthcare Organization
Revenue Recognition
Upfront payment		$ 20,000,000
Initial Payment Received		$ 20,000,000